

639699

Commonwealth of Australia

SPRUSON & FERGUSON

Patents Act 1990

PATENT REQUEST: STANDARD PATENT

We, the Applicants/Nominated Persons specified below, request we be granted a patent for the invention disclosed in the accompanying standard complete specification.

[70,71] Applicants/Nominated Persons:

The Salk Institute for Biological Studies, of 10010 North Torrey Pines Road, La Jolla, California, 92037, United States of America

[54] Invention Title:

Dominant Negative Members of the Steroid/Thyroid Superfamily of Receptors

[72] Inventors:

Ronald Mark Evans
Stanley Mark Hollenberg
Anthony Eugene Oro
Klaus Damm
Richard Alan Heyman

[74] Address for Service in Australia:

Spruson & Ferguson, Patent Attorneys
Level 33 St Martins Tower
31 Market Street
Sydney New South Wales Australia [Code SF]

[31] Basic Convention Application Details
Application No {33} Country {32} Date of Application
358,696 United States 26 May 1989

[62] Divisional Application Details
Original Application: 49562/90

DATED this FOURTH day of DECEMBER 1991
The Salk Institute for Biological Studies


Michael O'Leary
Registered Patent Attorney

P/00/008

Australia

SPRUSON & FERGUSON

Patents Act 1990

NOTICE OF ENTITLEMENT

I, Delbert Ernest Glanz, of 10010 North Torrey Pines Road, La Jolla, California 92037, United States of America, being authorised by the Applicant/Nominated Person in respect of Application No 58248/90 state the following:-

The Applicant/Nominated Person has entitlement from the actual inventors as follows:-

The Applicant/Nominated Person is the assignee of the actual inventors.


The Applicant/Nominated Person has entitlement from the applicants of the basic application listed on the Patent Request as follows:

The Applicant/Nominated Person is the assignee of the basic applicants.

The basic application listed on the Patent Request is the application first made in a Convention country in respect of the invention.

The Applicant/Nominated Person is the applicant of the original application.

DATED this 18 day of SEPTEMBER 1992


Delbert Ernest Glanz

(12) PATENT ABRIDGMENT (11) Document No. AU-B-58248/90
 (19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 639699

(54) Title
DOMINANT NEGATIVE MEMBERS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS

(51) International Patent Classification(s)
 C07K 015/06 C07K 013/00 C12N 015/12 G01N 033/74
 A01K 067/027

(21) Application No. : 58248/90 (22) Application Date : 25.05.90

(87) PCT Publication Number : WO90/14356

(30) Priority Data

(31) Number (32) Date (33) Country
 358696 26.05.89 US UNITED STATES OF AMERICA

(43) Publication Date : 18.12.90

(44) Publication Date of Accepted Application : 05.08.93

(62) Related to Division(s) : 49562/90

(71) Applicant(s)
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

(72) Inventor(s)
RONALD MARK EVANS; STANLEY MARK HOLLENBERG; ANTHONY EUGENE ORO; KLAUS DAMM; RICHARD ALAN HEYMAN

(74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

(56) Prior Art Documents
 AU 49562/90 C12N 15/12 A01K 67/09 C07K 15/06
 AU 28188/89 C12N 15/12
 AU 816389 82388/87 C07H 21/04 C12N 15/12 G01N 33/74

(57) Claim

1. A trans-repressing analog receptor of the steroid/thyroid superfamily of receptors, said analog comprising:

(1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of a wild type receptor, and

(2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said second sequence is selected from:

(a) a polypeptide which has at least about 90 % as many amino acids as the ligand binding domain of the carboxy-terminal portion of said wild type receptor; wherein said polypeptide and has less than about 60 % amino acid identity relative to the carboxy-

terminal domain of said wild type receptor over either:

(i) the entire length of said polypeptide, if shorter than the carboxy-terminal domain of said wild type receptor, or

(ii) any segment of said polypeptide having the same length as the carboxy-terminal domain of said wild type receptor, or

(b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the *v-erbA* protein as defined by amino acid numbers 555-639 (see Figure 1);

provided that when said wild type receptor is a glucocorticoid receptor, said second amino acid sequence is not (a).

20. A non-human transgenic mammal, having disease symptoms due to an inability to respond normally to a steroid or thyroid hormone, wherein at least a subset of the cells of said mammal are capable of expressing an analog receptor of the steroid/thyroid superfamily of receptors according to any one of Claims 1 to 13 for one of said hormones, and wherein said analog receptor has trans-repression activity greater than that of its corresponding wild type receptor and trans-activation activity less than that of its corresponding wild type receptor.

OPI DATE 18/12/90

APPLN. ID 58248 / 90

PCT

AOJP DATE 07/02/91

PCT NUMBER PCT/US90/03113

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 3/00, 13/00, 15/00 C07K 17/00, C12P 21/00		A1	(11) International Publication Number: WO 90/14356 (43) International Publication Date: 29 November 1990 (29.11.90)
(21) International Application Number: PCT/US90/03113 (22) International Filing Date: 25 May 1990 (25.05.90)		(74) Agents: WATT, Phillip, H. et al.; Fitch, Even, Tabin & Flannery, Room 900, 135 South LaSalle Street, Chicago, IL 60603 (US).	
(30) Priority data: 358,696 26 May 1989 (26.05.89) US		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 358,696 (CIP) 26 May 1989 (26.05.89)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92138 (US).		639699	
(72) Inventors; and (75) Inventors/Applicants (for US only) : EVANS, Ronald, Mark [US/US]; 8615 La Jolla Scenic Drive North, La Jolla, CA 92037 (US); HOLLENBERG, Stanley, Mark [US/US]; 240 23rd Street, Del Mar, CA 92014 (US); ORO, Anthony, Eugene [US/US]; 4812 Mt. Etna Drive, San Diego, CA 92117 (US). DAMM, Klaus [DE/DE]; Klag-enfurterstrasse 25, D-8000 Münich (DE). HEYMAN, Richard, Alan [US/US]; 147 Honeycomb Court, Encinitas, CA 92024 (US).			

(54) Title: DOMINANT NEGATIVE MEMBERS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS

(57) Abstract

Disclosed are novel trans-repressing analog receptors wherein the ligand-binding domain(s) are modified versus wild type receptor, such novel receptors having repressed trans-activation transcription activation properties. Also disclosed are recombinant methods and means for preparing such receptors and assays using such receptors.

DOMINANT NEGATIVE MEMBERS OF THE STEROID/THYROID
SUPERFAMILY OF RECEPTORS

Related Applications

This is a continuation-in-part application of U.S. Patent Application Serial No. 07/358,696, filed 26 May 1989, which is in turn, a continuation-in-part application of U.S. Patent Application Serial No. 07/289,561 filed 23 December 1988, the entire contents of which are both hereby incorporated by express reference herein.

10 Field of the Invention

The present invention relates to trans-repressing analog receptors of the steroid/thyroid superfamily. In a particular aspect, it relates to the identification and characterization of proteins that function as transcription trans-activation repressors, as well as to their preparation and use, including novel DNA isolates encoding same; expression vectors operatively harboring these DNA sequences; and hosts transfected with said vectors.

20 In another aspect, the present invention relates to the use of the above-described transcription trans-activation repressors in various assays and screening methods.

25

Background of the Invention

The characterization and preparation of various hormone and hormone-like receptors, including steroid,

-2-

thyroid, and retinoid receptors such as those represented by the glucocorticoid, mineralocorticoid, thyroid, estrogen-related and retinoid classes has been subject of considerable research.

5 It is known, for example, that the glucocorticoid receptor belongs to a large superfamily of ligand-dependent transcription factors that have themselves diverse roles in homeostasis, growth and development. Comparison of complementary DNAs encoding 10 these receptors, as well as mutational analyses of their coding sequences, have identified certain functional domains within the molecule that are thought responsible respectively for DNA binding, hormone binding and nuclear localization. See Evans, *et al.*, *Science* 240, 889 (1988) 15 for a review of this subject matter.

In the case of the glucocorticoid receptor, the so-called DNA binding domain spans some sixty-six amino acids and is highly conserved among various species. In addition, this domain has been found to be required in 20 order to activate transcription. See Hollenberg, *et al.*, *Cell* 49, 39 (1987), Miesfeld, *et al.*, *Science* 236, 423 (1987), Danielsen, *et al.*, *Mol. Endo* 1, 816 (1987), Kumar, *et al.*, *Cell* 51, 941 (1987), Gronemeyer, *EMBO J.* 6, 3985 (1987), and Waterman, *et al.*, *Mol. Endo* 2, 14 (1988). 25 This domain has been found to contain nine invariant cysteine residues. Although the contribution of each cysteine residue to overall function is unknown, as is the actual structure formed by this domain, it has been proposed that these cysteine residues coordinate two zinc ions to form two DNA binding, so-called finger domains, which result in a ternary structure thought responsible 30 for the localization and binding of the glucocorticoid receptor to the requisite DNA site. See Klug, *et al.*,

-3-

Tk.Biochem.Sci 12, 464 (1987), Bens, et al., Cell 52, 1 (1988), and Evans, supra.

5 In a location nearer the carboxyl-terminal end distal from the DNA binding region is the so-called ligand binding domain which has the demonstrated ability to block activity of the receptor in the absence of hormone. Thus, presence of the requisite hormone relieves the inhibition of the receptor to activity. Deletion of this region has been found to produce a 10 hormone-independent transcription activator. See Godowski, et al., Nature 325, 365 (1987), Hollenberg, et al., supra, Kumar, et al., supra, Danielsen et al., supra, and Adler et al., Cell 52, 685 (1988).

15 In contrast to these two domains, the sequences lying towards the amino-terminal region from the DNA binding domain are poorly understood both as to structure, and particularly, function. This region is extremely variable both in size and in composition amongst the various receptors - See Evans, supra - and 20 may contribute to the heterogeneity of receptor function. See Kumar et al., supra, and Tora et al., 333, 185 (1988).

25 Despite extensive analysis, some of which has been reported in the scientific literature, the region(s) that determine(s) trans-activation of transcription initiation remains poorly characterized. Trans-activation domains can be defined as polypeptide regions that, when combined with the functional DNA binding domain, increase productive transcription initiation by 30 RNA polymerases. See Sigler, Nature 333, 210 (1988), Brent et al., Cell 41, 729 (1985), Hope et al., Cell 46, 885 (1986), Ma et al., Cell 48, 847 (1987), Ma et al., Cell 51, 113 (1987), Lech et al., Cell 52, 179 (1988), and Hope et al., Nature 333, 635 (1988).

-4-

Previous research of the human glucocorticoid receptor by linker scanning mutagenesis identified two regions outside of the DNA binding region having a role in transcription activation. These regions were defined 5 as τ_1 and τ_2 . Giguere *et al.*, Cell 46, 645 (1986). Further research from these laboratories has also resulted in the report of a co-localization of trans-activation and DNA binding functions. See Hollenberg *et* 10 *al.*, supra, Miesfeld, *et al.*, supra, Danielsen *et al.*, supra, and Waterman *et al.*, supra. As a result, this research has given rise to an emerging picture of an increasingly modular molecule with discrete domains, each contributing to the identified properties of ligand-binding, DNA-binding and trans-activation of 15 transcription. Until recently, the region(s) determining the trans-activation activity were not at all well understood. Thus, the picture based upon extant literature lacks an overall appreciation of the dynamic nature of the steroid receptors and how the various 20 domains determine the cascade of events initiated by ligand-binding and consummated by promoter-specific trans-activation.

Further, although previous research has identified functional "domains", there has been little 25 systematic effort to identify amino acids that contribute to the specific activities of the molecule itself. Thus, the previous identification of steroid receptor trans-activation regions resulted only from a demonstrated loss of activity via deletion or insertional mutagenesis, but in no case have the properties of the regions themselves 30 been confirmed in assays that reflect a dominant gain of function. See also Ptashne, Nature 335, 683 (1988).

Thus, Godowski *et al.*, Science 241, 812 (1988), report results that show that the glucocorticoid receptor

-5-

contains at least one "enhancement domain" other than that overlapping the glucocorticoid response element binding region (i.e., the DNA binding domain) and that the second domain occupies a region near the receptor 5 amino-terminus. Similarly, Webster *et al.*, Cell 54, 199 (1988) report on an inducible transcription activation function of the estrogen and glucocorticoid receptors, and these researchers speculate that the relative 10 positions of the hormone regions (i.e., ligand and DNA-binding domains) are not important for the transcription induction activity of the receptor. Yet, these 15 researchers admit that they have no definition of the exact location and nature of what they call the hormone-inducible activating domain, to say nothing of its characterization and role in trans-activating potential.

The work by Giguere *et al.*, supra, demonstrated a loss of activity in the glucocorticoid receptor based upon an assay measuring transcription activity, as a result of performing random site-mutagenesis at several locations of the molecule. As a 20 follow-up, Hollenberg *et al.* deleted regions in the molecule, again demonstrating overall loss of transcription activity induced by such removal of stretches of amino acids.

25 The human glucocorticoid receptor (hGR) has served as a prototype, model receptor for gene regulation. As noted above, the DNA-binding and ligand-binding functional domains have been defined previously. Similarly, it has been found that these modular domains 30 of the hGR receptor or other receptors may be moved to other parts of the receptor or attached to heterologous DNA-binding domains and still maintain function.

In contrast, relatively little is known about negative regulation by hGR. This is surprising in light

-6-

of the key role that steroids play in development and negative feedback regulation. Glucocorticoid helps determine neural crest cell fate in the developing sympathoadrenal system, in part by repressing the
5 induction of neural-specific genes [See Stein *et al.*, *Dev Bio* 127, 316 (1988) and Anderson *et al.*, *Cell* 47, 1079 (1986)]. Glucocorticoid also modulates the hypothalamic-pituitary-adrenal axis by inhibiting second messenger-induced peptide hormone induction. Recently, Akerblom *et*
10 *al.* (*Science* 241, 350 (1988)) showed that the hGR negatively regulates the cyclic AMP-inducible alpha glycoprotein hormone promoter in a steroid and DNA-binding dependent manner. Wild-type expression is exhibited by a promoter of just 168 base pairs (termed
15 alpha168). Basal expression in placental cells is mediated by factors bound to a 36 base pair palindromic cyclic AMP response element (CRE) cooperating with proteins binding to a 25 base pair tissue-specific element (TSE). Expression may be further enhanced
20 through the CRE by the elevation of intracellular cyclic AMP levels. The hGR represses both the basal and cyclic AMP enhanced transcription in a glucocorticoid-dependent fashion. The transacting elements to which the hGR binds have been defined and are related to the consensus GRE
25 sequence for activation. Similar research is reported by Sakai, *et al.*, *Genes and Development* 2, 1144 (1988).

Summary of the Invention

The present invention is the result of a thorough analysis of the structural requirements of hormone receptors for repression. This analysis has revealed an absolute requirement for the DNA binding domain and a role for the carboxyl terminus for repression. Although the DNA-binding domain alone is not
30

-7-

sufficient for maximal repression, the addition of polypeptides to the carboxyl terminus or other modifications as described herein at the carboxyl terminus leads to the creation of novel fusion proteins
5 having dominant negative repressor activity.

In accordance with the present invention, we have identified, isolated and characterized the domains of intracellular hormone or hormone-like receptors that can be modified so as to repress trans-activation
10 transcription activity. This information has enabled the further characterization of various receptors of the steroid/thyroid superfamily, both in terms of physical attributes and biological function and effect of various domains, particularly that domain capable of being
15 modified to provide repressed transcription activity. The foregoing has in turn enabled the production of novel analog receptors having repressed transcription activation properties.

It has been determined, based upon the
20 information provided herein, that receptors of the steroid/thyroid superfamily contain domains that function in overall trans-activation transcription activity, even though the three receptor domains, i.e., the DNA-binding, the ligand-binding, and the trans-activation
25 transcription domains, are positioned independently of one another and are autonomous in function. In accordance with the present invention, it has been discovered that the carboxyl terminus of a given receptor is that domain responsible for modulating the trans-activation transcription activity of said receptor. It
30 has further been found that the DNA-binding domain is a necessary component in any receptor hereof having repressed trans-activation transcription activity.

-8-

This invention provides for novel hormone or hormone-like analog receptors wherein the trans-activation transcription activity is repressed. Such novel analog receptors contain a DNA-binding domain, 5 optionally an N-terminal domain and a C-terminal domain that has been altered so as to provide repressed trans-activation transcription activity compared with parental or wild-type receptor. The novel analog receptors hereof may be hybrid receptors wherein the DNA-binding domain, 10 N-terminal domain and C-terminal domain are provided from different sources. For example, the C-terminal domain of the glucocorticoid receptor can be replaced herein by a portion of the C-terminus of the v-erbA protein. Alternatively, the C-terminal domain of the 15 glucocorticoid receptor can be replaced with at least a portion of a polypeptide such as β -galactosidase.

The present invention is further directed to the preparation of such novel analog receptors hereof via recombinant DNA technology in all relevant aspects, 20 including a DNA molecule that is a recombinant DNA molecule or a cDNA molecule consisting of a sequence encoding said analog receptor or a C-terminal modified domain thereof, requisite expression vectors operatively harboring such DNA comprising expression control elements 25 operative in the recombinant hosts selected for the expression, and recombinant host cells transfected with such operative expression vectors.

The present invention is also directed to the use of the novel analog receptors described herein for identifying the response element and/or function of an "orphan" receptor, i.e., a receptor for which the associated response element and/or function is not known. 30

The present invention is further directed to the use of the novel analog receptors described herein in

-9-

an improved assay system for the determination of a specific wild type receptor, wherein more than one response element present in the assay system is capable of interacting with the wild type receptor.

5 An additional utility for such repressed analog receptors hereof lies in the area of cancer therapy. Certain cells require augmented levels of hormone in order to become tumorigenic. One example is the elevated estrogen requirement observed in mammary tumors. Indeed,
10 estrogen antagonists, such as tamoxifin, are used in therapy so as to decrease the amount of estrogen available so that the transformation of normal mammary cells into tumorous cells is inhibited. Alternatively,
15 the analog receptors of the present invention can be used for such purpose.

Brief Description of the Figures

Figure 1 provides the amino acid sequence of the v-erbA protein.

20 Figure 2 is a dose response curve for hGR-mediated negative regulation.

Figure 3 illustrates the repression by carboxyl terminal fusion proteins.

25 Figure 4 illustrates several expression and reporter constructs.

Figure 5 shows the structure and activity of rat TR α /v-erbA chimeric proteins.

30 Figure 6 shows a comparison of T₃ induction of CAT activity by thyroid receptor, v-erbA, and hybrid Tr/v-erbA receptors.

Figure 7 shows the competition of TR α or v-erbA with RA induced transcriptional activation by RAR α .

Figure 8 summarizes the structure and activity properties of several RAR hybrids and mutants.

-10-

Figure 9 shows the competition of RA induction by RAR α -v erbA fusion protein.

5 Figure 10 shows the competition of RA induced transactivation of endogenous RARs in F9 tetracarcinoma stem cells.

10 Figure 11 summarizes the structure and activity of several GR hybrids and mutants.

Detailed Description of the Invention

In accordance with the present invention, there is provided a trans-repressing analog receptor of the steroid/thyroid superfamily of receptors, said analog comprising:

15 (1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of a wild type receptor, and

20 (2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said second sequence is selected from:

25 (a) a polypeptide which has at least about 90 % as many amino acids as the ligand binding domain of the carboxy-terminal portion of said wild type receptor; wherein said polypeptide has less than about 60 % amino acid identity relative to the carboxy-terminal domain of said wild type receptor over either

30 (i) the entire length of said polypeptide, if shorter than the carboxy-terminal domain of said wild type receptor, or

(ii) any of said polypeptide segments having the same length as the carboxy-terminal domain of said wild type receptor; or



- (b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the v-erbA protein as defined by amino acid numbers 313-398 (see Figure 1; Note that the erb-A amino acid numbering will vary by about 255 amino acids depending on whether the gag sequence (the 5 amino-terminal 255 amino acids) is included for purposes of numbering the amino acids of the erb-A protein).

In accordance with another embodiment of the present invention, there is (are) provided expression vector(s) operatively harboring DNA 10 molecule(s) which is (are) recombinant DNA molecule(s) or cDNA molecule(s) encoding the above-described receptor analogs; recombinant host cells transfected with such expression vectors; and cell cultures comprising such cells in an extrinsic support medium.

15 In accordance with yet another embodiment of the present invention, there is provided a non-human transgenic mammal, having disease symptoms due to the inability to respond normally to a steroid or thyroid hormone, said mammal having at least a subset of its cells capable of expressing an analog receptor for one of said hormones, said analog receptor having 20 trans-repression activity greater than that of its corresponding wild type receptor and trans-activation activity less than that of its corresponding wild type receptor.

25 In accordance with still another embodiment of the present invention, there is provided a method for converting a wild type hormone receptor into a trans-repressing analog receptor of the steroid/thyroid superfamily or receptors, said method comprising:

30 replacing the ligand binding domain of said wild type receptor with at least the 84 carboxy terminal amino acids of the verbA protein as defined by amino acid numbers 313-398 (see Figure 1).

This latter embodiment of the present invention can alternatively be accomplished by replacing the ligand binding domain of said wild type receptor with a polypeptide which has at least 90% as many amino acids as



at least the ligand binding domain of the carboxy-terminus of said wild type receptor; and wherein said polypeptide has less than about 60% amino acid identity relative to the carboxy-terminus of said wild type receptor over either:

5

(i) the entire length of said polypeptide, if shorter than the carboxy-terminus of said wild type receptor, or

10 (ii) any segment of said polypeptide having the same length as the carboxy-terminus of said wild type receptor.

In accordance with a further embodiment of the present invention, there is provided a method for blocking the transcriptional activation by a wild type receptor of a hormone response element in a 15 cell by contacting the cell with an effective amount of an analog receptor as described hereinabove.

In accordance with a still further embodiment of the present invention, there is provided a method for blocking the transcriptional activation by a wild type receptor of the steroid/thyroid superfamily of receptors of a hormone response element present in a cell, said method comprising

25 (a) substantially deleting the ligand binding domain of said wild type receptor,

30 (b) operatively linking the modified receptor of step (a) at the carboxy-terminal end thereof to at least the 84 carboxy terminal amino acids of the verbA protein as defined by amino acid numbers 313-398 (see Figure 1) to produce a fusion protein, and thereafter

30 (c) contacting said cell with an effective amount of said fusion protein.

This latter embodiment of the present invention can alternatively be accomplished by:



(a') substantially deleting the ligand binding domain of said wild type receptor;

(b') operatively linking the modified receptor of step (a') at the carboxy-terminal end thereof to a polypeptide which has at least about

5 90% as many amino acids as the ligand binding domain of said wild type receptor, wherein said polypeptide has less than about 60% amino acid identity relative to the ligand binding domain of said wild type receptor over either

(i) the entire length of said polypeptide, if shorter than
10 the ligand binding domain of said wild type receptor, or

(ii) any segment of said polypeptide having the same length as the ligand binding domain of said wild type receptor,
to produce a fusion protein, and thereafter

(c) contacting said cell with an effective amount of said fusion
15 protein.

In accordance with another embodiment of the present invention, there is provided a method for identifying the response element and/or function of a receptor for which the associated response element and/or
20 function is not known, said method comprising:

comparing the response of a test system having known responsiveness to wild-type receptor to the response of said test system when treated with trans-repressing analog receptor of the steroid/thyroid superfamily of receptors; wherein said trans-repressing analog receptor comprises:

25

(1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of said wild type receptor, and

30 (2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said sequence is selected from:

(a) a polypeptide which has at least about 90% as many amino acids as the ligand binding domain of the carboxy-terminal portion of said wild type receptor; wherein said polypeptide has less than about 60% amino acid identity relative to the carboxy-terminal domain of said wild type



receptor over either:

the entire length of said polypeptide if shorter than the carboxy-terminal domain of said wild type receptor, or

- 5 any segment of said polypeptide having the same length as the carboxy-terminal domain of said wild type receptor; or

(b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the *v-erbA* protein as defined by amino acid numbers 313-398 (see Figure 1).

- 10 For example, the specific response element(s) with which the orphan receptor interacts can be determined by screening a variety of test systems, each having a single known response element. The response element of the specific test system which is activated by the orphan receptor, but which is repressed by an analog receptor derived from the orphan receptor according to the present invention, is the response element for the orphan receptor.

Similarly, the function of an orphan receptor can be determined by comparing the response of a test system when contacted with the orphan receptor, relative to the response of the same test system when contacted with a trans-repressing analog of the orphan receptor according to the present invention. Differences in the response in the two side-by-side comparisons provide an indication of the functional role of the orphan receptor.

In accordance with yet another embodiment of the present invention, an improvement is provided for use in assay systems responsive to the presence of a specific wild type receptor, wherein more than one response element is capable of interacting with said wild type receptor, the improvement comprising inactivating, with respect to said assay, response element(s) which also respond to wild type receptor(s) other than said specific receptor; wherein said response elements are inactivated by adding to said assay system an effective amount of a trans-repressing analog receptor of the steroid/thyroid superfamily of receptors for each of said other receptor(s), wherein each of said trans-repressing analog receptors comprises:

LACI
5
r OF

(1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of a receptor other than said specific wild type receptor, and

1
2
3
4
5



-16-

(2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said sequence is selected from:

5

(a) a polypeptide which has at least about 90% as many amino acids as the ligand binding domain of the carboxy-terminal portion of said receptor other than said specific wild type receptor; wherein said polypeptide has less than about 60% amino acid identity relative to the carboxy-terminal domain of said receptor other than said specific wild type receptor over either:

10

the entire length of said polypeptide if shorter than the carboxy-terminal domain of said receptor other than said specific wild type receptor, or

15

any segment of said polypeptide having the same length as the carboxy-terminal domain of said receptor other than said specific wild type receptor; or

20

(b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the *v-erbA* protein as defined by amino acid numbers 313-398 (see Figure 1).

25

As employed herein, the term "dominant

30

negative", when used in reference to the analog receptors of the present invention, refers to species which have a negative effect on the transcriptional activation activity of the associated response element, even in the presence of wild-type receptor and its associated ligand.

-17-

Amino acid abbreviations employed in the present disclosure use the following standard single- and three-letter designations, i.e.:

	Asp	D	Aspartic acid	Ile	I	Isoleucine
5	Thr	T	Threonine	Leu	L	Leucine
	Ser	S	Serine	Tyr	Y	Tyrosine
	Glu	E	Glutamic acid	Phe	F	Phenylalanine
	Pro	P	Proline	His	H	Histidine
	Gly	G	Glycine	Lys	K	Lysine
10	Ala	A	Alanine	Arg	R	Arginine
	Cys	C	Cysteine	Trp	W	Tryptophan
	Val	V	Valine	Gln	Q	Glutamine
	Met	M	Methionine	Asn	N	Asparagine

15 Receptors employed in the practice of the present invention can be prepared by recombinant techniques, by synthetic chemistry, or the like. The thus produced receptor, in its various forms, is recovered and purified to a level suitable for its intended use.

20 The existence of a superfamily of ligand-inducible trans-acting factors is now recognized, including those for steroid hormones, retinoic acid and vitamin D3, two subtypes (isoforms) of thyroid hormone receptors (termed α and β), and the like. Mutational analysis and structural comparisons of these hormone receptors has enabled the identification of domains responsible for hormone-binding, DNA-binding and trans-activation of gene expression. See Sap *et al.*, *Nature* 324, 635 (1986), Weinberger *et al.*, *Nature* 324, 641 (1986) and Evans, *Science* 240, 889 (1988).

25 The receptors of the present invention are trans-repressing analogs of hormone or hormone-like receptors which are referred to broadly as members of the

-18-

steroid/thyroid superfamily of receptors, e.g., glucocorticoid receptor, mineralocorticoid receptor, progesterone receptor, estrogen receptor, estrogen-related receptors, vitamin D₃ receptor, thyroid hormone receptor, retinoic acid receptor, aldosterone receptor, androgen receptor, and the like. Receptors of the 5 present invention include functional equivalents of all of the above, including receptors differing in one or more amino acids from the corresponding parent, or in glycosylation and/or phosphorylation patterns, or in bounded conformational structure. The terminology "functional equivalents thereof" refers to trans-repressing analog receptors which differ from the 10 previously described analog receptor(s) with respect to one or more amino acids, insofar as such differences do not lead to a destruction in kind of the basic repressed 15 receptor activity or biofunctionality.

It will be understood, therefore, that 20 receptors that are known in the art, whether wild-type, hybrids, or functional equivalents as set forth herein, are suitable as starting materials for the practice of the present invention.

As employed herein, the term "expression 25 vector" includes vectors which are capable of expressing DNA sequences contained therein, where such sequences are operatively linked to other sequences capable of effecting their expression. It is implied, although not always explicitly stated, that these expression vectors may be replicable in host organisms either as episomes or 30 as an integral part of the chromosomal DNA. As employed herein, the term "operative," or grammatical equivalents, means that the respective DNA sequences are operational, that is, work for their intended purposes. In sum, "expression vector" is given a functional definition, and

-19-

any DNA sequence which is capable of effecting expression of a specified DNA sequence disposed therein is included in this term as it is applied to the specified sequence. In general, expression vectors of utility in recombinant 5 DNA techniques are often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their vector form, are not bound to the chromosome. In the present specification, the terms "plasmid" and "vector" are used interchangeably as the plasmid can be a commonly used form of vector. However, the invention is intended to include such other forms of expression 10 vectors which serve equivalent functions and which become known in the art subsequently hereto.

As employed herein, the term "recombinant host 15 cells" refers to cells which have been transfected with vectors constructed using recombinant DNA techniques.

As employed herein, the term "extrinsic support medium" includes those known or devised media that can support cells in a growth phase or maintain them in a viable state such that they can perform their recombinantly harnessed function. See, for example, ATCC Media Handbook, Ed. Cote et al., American Type Culture Collection, Rockville, MD (1984). A growth supporting medium for mammalian cells, for example, preferably contains a serum supplement such as fetal calf serum or other supplementing component commonly used to facilitate cell growth and division such as hydrolysates of animal meat or milk, tissue or organ extracts, mace, fat clots or their extracts, and so forth. Other suitable medium components include, for example, transferrin, insulin and various metals.

The vectors and methods disclosed herein are suitable for use in host cells over a wide range of prokaryotic and eukaryotic organisms.

-20-

In addition to the above discussion and the various references to existing literature teachings, reference is made to standard textbooks of molecular biology that contain definitions and methods and means for carrying out basic techniques encompassed by the present invention. See, for example, Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982 and the various references cited therein, and in particular, Colowick et al., Methods in Enzymology Vol 152, Academic Press, Inc. (1987). All of the herein cited publications are by this reference hereby expressly incorporated herein.

Non-human transgenic organisms contemplated by the present invention include rodents (e.g., mice, rats), pigs, sheep, lower eukaryotes (e.g., *Drosophila*, *Xenopus*), and the like.

Transcriptional activation by the steroid receptors and the thyroid hormone receptors has been found to be dependent on the presence and binding of the respective ligand. However, deletion analysis has disclosed that glucocorticoid, estrogen, and progesterone receptors lacking the hormone binding domain still recognize the specific response elements and may function as constitutive activators. Thus, neither the ligand itself nor its binding domain need to participate directly in DNA recognition.

The v-erbA protein has been found to contain an apparently intact DNA-binding domain; however, as a result of amino-acid changes and a deletion in the carboxy-terminal domain (relative to its progenitor, the thyroid hormone receptor), it lacks the ability to bind thyroid hormone. By analogy to mutated steroid hormone receptors, it has been proposed that these mutations, in conjunction with the high level of expression, convert

-21-

the thyroid hormone receptor into v-erbA, which is a hormone independent transcription factor.

Utilizing a gel retardation assay, it has now been demonstrated that both v-erbA and the thyroid hormone receptor recognize and bind to a cognate response element in the absence of ligand. The consequence of this binding is the suppression of a thyroid hormone responsive reporter gene by the non-liganded receptor. Addition of thyroid hormone results in a 10-100 fold stimulation of transcription from the repressed level. Surprisingly, v-erbA does not function as an activator as one might expect, but rather as a constitutive repressor of T₃ responsive genes. When co-expressed with the thyroid hormone receptor, and in the further presence of thyroid hormone, the v-erbA repression is dominant, blocking hormone stimulated modulation, thereby demonstrating that v-erbA can function as a potent receptor antagonist.

The present invention thus embraces hormone or hormone-like receptor analogs having the ability to repress trans-activation transcription activity of a promoter with which it is associated, or an extrinsic, operative promoter. Such repression is due, for example, to the intrinsic ability of the analog receptor to competitively bind to a DNA response element of said promoter or by the ability of the analog receptor to competitively displace other polypeptide(s) that bind to said DNA response element, or a proximate DNA response element, thus creating an overall repression of trans-activation transcription activity compared with that of its corresponding parent or wild-type receptor.

-22-

EXAMPLES

The following experimental details set forth the methodology employed in identifying, characterizing and preparing particular novel analog receptors. The art skilled will recognize that by supplying the present information including the location and makeup of trans-activation transcription repression domain(s) of a given receptor and how such receptor can be manipulated to produce the novel analog receptors hereof having repressed trans-activation transcription activity, it is not necessary, or perhaps scientifically advisable, to repeat the details described herein to reproduce this work. Instead, they may choose to employ alternative, reliable and known methods. For example, they may synthesize the underlying DNA sequences encoding a particular novel receptor hereof for deployment within similar or other suitable, operative expression vectors and culture systems. Thus, in addition to supplying details actually employed, the present disclosure serves to enable reproduction of the specific receptors disclosed, as well as others, and fragments thereof, using means within the skill of the art having benefit of the present disclosure. All of such means are included within the enablement and scope of the present invention.

25

Example 1: Transfections

Transfections in JEG-3 human placental cells are performed via the calcium phosphate precipitation method described by Delegeane et al, Mol. Cell. Biol., Vol. 7, pp. 3994-4002 (1987). JEG-3 cells, maintained in Dulbecco's modified Eagle's medium (DMEM), 10 percent defined calf bovine serum (CBS), and 0.4 percent glucose are split 24 hours prior to transfection into 5 percent CBS charcoal-stripped serum plus glucose (Akerblom et

-23-

al., Science 241, pp. 350-353 (1988)). Typically, 2 μ g of reporter plasmid and 4 μ g of receptor plasmid were used along with 2 μ g of a Rous sarcoma virus (RSV)- β -galactosidase construct (Hollenberg et al., Cell 49, pp. 39-46 (1987)) as an internal control for transfection efficiency. Dexamethasone and aldosterone (10^{-7} M) were added after calcium phosphate treatment. For the β -galactosidase fusion experiments, the internal control was RSV-luciferase.

Transfections in CV-1 cells are also performed via the calcium phosphate precipitation method. CV-1 cells are maintained in DMEM supplemented with 5% calf bovine serum and transfected at 30%-50% confluence with a total of 20 μ g DNA. 5 μ g expression plasmid and 2.5 μ g reporter plasmid DNA, together with 2.5 μ g RSV- β -gal as an internal control for transfection efficiency, are cotransfected per 10 cm dish. Transfected cells are grown in 10% resin-treated fetal calf serum [Samuels et al., J. Endocrinology, Vol. 105, pp. 80-85 (1979)] in the presence or absence of 10^{-7} M 3,5,3' triiodothyronine (T_3). Cells are harvested 40 hours after the addition of T_3 ; β -galactosidase and CAT-assays are then performed as described in Example 2.

Example 2: Reporter Assays

Chloramphenicol acetyltransferase (CAT) assays are performed as described by Hollenberg, et al., Cell, Vol. 49, pp. 39-46 (1987), but with 25 μ g of total cell extract protein for 3 hours or less. Thin-layer chromatography (TLC) plates are cut and counted in Econofluor containing 5% dimethyl sulfoxide (DMSO).

β -Galactosidase (β -gal) assays are performed as described by Herbomel, et al. Cell, Vol. 29, pp. 653-662 (1984).

-24-

Example 3: hGR Mediated Negative Regulation

To demonstrate hGR-mediated repression of the alpha168 promoter (a promoter for the alpha-subunit gene encoding chorionic gonadotropin; which is repressed by GR), a dose response study is conducted of negative regulation of the alpha168-CAT reporter plasmid by the hGR expression plasmid in human placental JEG-3 cells. Varying amounts of the hGR expression plasmid (driven by the RSV promoter) and alpha168-CAT (reporter) expression plasmid are cotransfected by the calcium phosphate precipitation method. Cotransfections are carried out so as to provide increasing receptor to promoter ratios. The resultant transient CAT activity in the presence or absence of the steroid hormone dexamethasone is then measured. Throughout the study, the total amount of transfected RSV promoter DNA is kept constant by substituting an RSV control plasmid, thus controlling for possible titration of transcription factors by RSV DNA. The CAT activity of the reporter construction is measured as described above.

The alpha168-CAT reporter plasmid is constructed as described by Delegeane et al., supra.

The hGR expression plasmid, driven by the RSV promoter, is constructed as described by Hollenberg et al, Cell, Vol. 49, pp. 39-46 (1987).

Control plasmid RSV contains the rat thyroid hormone receptor coding region in the antisense direction, and is described by Thompson et al, in Science, Vol. 237, pp. 1610-1614 (1987).

Figure 2 shows the effect of the transfection of hGR cDNA on reporter gene expression in the presence and absence of dexamethasone. Open circles in the Figure indicate media without added dexamethasone, while solid

-25-

circles indicate media with added dexamethasone (10^{-7} M). In the particular experiment presented in Figure 2, 2 μ g of promoter plasmid is used. The arrow indicates the ratio of receptor to promoter used in subsequent experiments.

Figure 2 shows that increasing amounts of the receptor expression plasmid yield a correspondingly higher steroid-dependent repression. In the absence of receptor cDNA, less than 10 percent of maximal repression is measured. Beginning at a receptor to promoter ratio of 1 and continuing to a ratio of 5, a plateau of repression activity emerges where more receptor plasmid yields no additional steroid-dependent repression. Since the amount of RSV promoter is held constant, this plateau indicates probable saturation of the site of receptor action. For subsequent experiments, a receptor to promoter ratio of 2:1 is used. The steroid-dependent repression varies between 6 and 20 fold with an average of 9 fold as typified in Figure 2. This assay can reliably measure as low as 10 percent of wild type hGR repression.

Figure 3 shows the relative CAT activity of wild-type hGR, truncated hGR's and several hGR fusion proteins. hGR fusion proteins are assayed as described above. For I582*, wild-type hGR (hgrwt), I532* and the I532*- β -galactosidase fusion, the hormone used is dexamethasone; for the fusion protein GGM, the hormone used is aldosterone.

In Figure 3B, the general make-up of the various hGR-derived proteins is illustrated. Thus, I582* is a truncated hGR having only 582 amino acids; I532* is a truncated hGR having only 532 amino acids; I532*- β -galactosidase is a fusion protein comprising amino acids I-532 from hGR, plus amino acids 8-1025 from β -

-26-

galactosidase, made by inserting the 3030 bp BamHI LacZ fragment of pBG-1, a derivative of pSK105, in frame into the BamHI site of I532 (Casadaban *et al.*, Methods in Enzymology Vol 100, 293, Academic Press (1983)); and GGM is a fusion protein constructed by first introducing an additional XhoI site into both the hGR at nucleotide position I596 (Hollenberg *et al.*, Nature 318, 635 (1985)) and the human mineralocorticoid receptor (hMR) at nucleotide position 2233 (Arriza *et al.*, Science 237, 268 (1987)) and then inserting the appropriate XhoI fragment of the hMR into the hGR. This gave a receptor with amino acids 1-489 of hGR and 671-984 of hMR.

Figure 3B compares the repression activity of the carboxy terminal fusion proteins on the alpha1⁶⁸ promoter to activation on the mouse mammary tumor virus (MTV) promoter. The percentage of wild type activity is calculated by assigning RSV control plasmid as zero activity and the wild type hGR as 100 percent in each experiment, plus or minus the standard error of the mean. Control 1 and control 2 refer to transfection with RSV control plasmid. Control 1 plus the next 4 constructions used dexamethasone as the steroid, while control 2 and GGM used aldosterone as the steroid. The numbers on the I532*-8-galactosidase construct refer to 8-galactosidase amino acid numbering from Casadaban *et al.*, Meth. Enzymol., Vol. 100, pp. 298-308 (1983), and the numbers on GGM refer to hMR amino acid numbering from Arriza *et al.*, SUPRA (1987). An "*" indicates that activity is less than 10 percent wild type repression activity, "++" indicates that activity is less than 1 percent wild type activation activity.

Novel sequence specific repressors can be created by attaching heterologous protein sequences to the carboxyl terminal side of the hGR DNA binding domain.

-27-

In one case, E. coli β -galactosidase (β -gal) can be fused in frame to the carboxyl terminal side of the hGR DNA-binding domain and assayed for regulatory properties. On the mouse mammary tumor virus (MTV) promoter, this hybrid functions as a constitutive activator with properties unchanged from that of the parental truncated receptor. On the alpha1 δ promoter, the fusion protein is a constitutive repressor whose activity is dramatically increased when compared to the truncated receptor, I532*. Thus, the addition of a heterologous E. coli protein sequence to the DNA binding domain of the hGR is sufficient for generation of a functional transcriptional repressor.

The results of this study provide several means to distinguish positive and negative regulatory effects of the hGR. First, the amino terminal domain that contains a potent activator sequence, τ_1 , is not necessary for trans-repression. Indeed, it has been found that deletion of τ_1 engenders a more potent repressor. This argues that even when functioning as a repressor, the amino terminal region of the hGR retains some residual positive activity.

The fact that certain modifications of the hGR produce a receptor that retains normal repressor function but has lost virtually all positive activation capability demonstrates that the process of activation can be mechanistically distinguished from that of repression. This observation further indicates that the function of the DNA-binding domain is more than simply to locate an appropriate regulatory sequence. Moreover, the result also implies that activation requires an additional event subsequent to DNA-binding that is apparently not critical for negative control.

-28-

Yet another distinction between activation and repression is that a β -galactosidase moiety functionally replaces the hGR carboxyl terminus only in repression. Removal of the carboxyl terminus results in a receptor variant with minimal repression activity.

5 **Example 4: Thyroid Receptor Mediated Negative Regulation**

10 Thyroid receptor (TR) differs from the glucocorticoid receptor (GR) in that the TR is able to bind to its cognate response element even in the absence of its associated ligand. In view of these differences, it is of interest to determine if modifications to the TR analogous to the modifications investigated for the GR will provide similar trans-repressing derivatives.

15 The vectors employed for these studies are prepared as follows:

20 Expression vector RS-rTR α is constructed as described by Thompson et al, Proc. of the Natl. Acad. of Sci., Vol. 86, pp. 3494-3498 (1989).

25 The expression plasmid RS-v-erbA is generated by excising the coding sequence of the cloned gag-v-erbA gene [Vennström et al., J. Virol. Vol. 36, pp. 575-585 (1980)], followed by appropriate modification of the 5' and 3' ends and insertion between the KpnI and BamH1 sites of the vector pRS-hGR α [Giguere et al., Nature 330, 624 (1987)]. Synthetic oligonucleotides encoding a palindromic response element [TRE β ; TCAGGTCA TGACCTGA; see Glass et al., Cell Vol. 54, pp. 313-323 (1988)] flanked by HindIII adaptor sequences are inserted into the unique HindIII cloning site in pBL-CAT2 [Luckow et al., Nuc. Acids Res. 15, 5490 (1987)]. Plasmids containing one or multiple copies of the TRE are identified by restriction enzyme mapping and sequence analysis. Hybrid genes are constructed using restriction sites common to both rTR α

-29-

[Thompson et al., *Science*, Vol. 237, pp. 1610-1614 (1987)] and v-erbA genes [Damm et al., *EMBO J.* Vol. 6, 375 (1987) and Vennström et al., *J. Virol.* 36, 575 (1980)]. A schematic organization of the rTR α and v-erbA protein sequences is given in Figure 3A. cDNAs encoding these proteins are cloned into an RSV expression vector. The "DNA" and "T₃/T₄" designations in the Figure refer to the DNA- and thyroid hormone binding domain, respectively. The 12 amino-terminal amino acids of chicken c-erbA/TR α are replaced by part of the retroviral gag-gene, resulting in the synthesis of a P75_{c-erbA} hybrid protein. In addition, v-erbA differs from chicken c-erbA/TR α in 2 amino acids in the DNA binding domain and 9 amino acids plus a 9 amino acid deletion in the hormone binding domain. The comparison to rat TR α shown in Figure 3A reveals an additional 17 amino acid differences that are species specific and also found in comparison between chicken and rat TR α deduced amino acid sequences. The numbers on top of the constructs shown in Figure 3A indicate amino acid positions.

TR(Δ154/317) is created by deleting the PstI fragment in the ligand binding domain of rTR α . Replacement of the rTR α carboxy-terminus by a PstI-XbaI fragment from a v-erbA-neo construct [Sap et al., *Nature* 324, 635 (1986)] generates TR(Δ154/317)erbA. The plasmids TR(317)erbA, TR(154erbA and TR(154/317) are generated by reinserting the PstI fragments from either rTR α or v-erbA into the unique PstI site of either plasmid. All modifications are performed on a subcloned fragment from the ligand binding domain of rTR α and hybrid expression constructs are generated by replacing the XbaI fragment of RS-rTR α with the corresponding chimeric fragments.

-30-

COS cells are grown in DMEM with 5% T3 free bovine serum and transfected using DEAE dextran [Giguere et al., Cell 46, 645 (1986)]. After 36 hours, cells are harvested and extracts prepared as described by Kumar et al., in Cell, Vol. 55, 145 (1988), except that the buffer was 20 mM Hepes (pH 7.8), 0.4 M KCl, 2 mM dithiothreitol (DTT) and 20% glycerol. DNA binding reactions and gel electrophoresis are performed essentially as described by Glass, et al., in Cell, Vol. 54, 313 (1988). Aliquots containing 6-10 µg of total protein are diluted so that the final concentration of KCl is 80 mM, then incubated with 2 µg of polydeoxycytidyllic acid (poly[dc]) for 20 min at room temperature. At this time, 25-50 fmoles of a ³²P-labeled oligonucleotide encoding the palindromic TRE was added. The reaction mixture was incubated at 22°C for 30 min and then loaded on a 5% polyacrylamide gel containing 50 mM Hepes pH 7.8. Competitor DNAs were added prior to the addition of the labeled oligonucleotide.

The DNA binding mutant i95TR was constructed by partial digestion of rTR α with PvUII and adding a BamHI linker (12mer) to restore the open reading frame. The position of the linker was verified by restriction enzyme mapping and sequence analysis.

The DNA binding mutant i95(154)erbA was constructed by partial digestion of TR(154)erbA with PvUII and adding a BamHI linker (12mer) to restore the open reading frame. The position of the linker was verified by restriction enzyme mapping and sequence analysis.

First, the transcriptional activity of both the rat thyroid hormone α receptor (rTR α) [Thompson, et al., Science 237, 1610 (1987)] and the v-erbA oncogene product is assessed by determining their ability to regulate

-31-

expression of thyroid hormone responsive reporter genes (see Fig. 4A). The constructs shown in the Figure contain oligonucleotides corresponding to previously identified thyroid hormone response elements [Glass *et al.*, Nature 322, 738 (1987) and Glass *et al.*, Cell 54, 313 (1988)] linked to a thymidine kinase-chloramphenicol acetyltransferase (tk-CAT) fusion gene [Luckow *et al.*, Nuc. Acids Res. 15, 5490 (1987)] (see Fig. 4B). The reporter gene constructs used, and shown in Figure 4B, contain oligonucleotides encoding the respective T₃ response elements (TRE) inserted into the HindIII site (H) upstream of the tk promoter-CAT construct. Expression plasmids encoding rTR_a or v-erbA under the transcriptional control of the RSV long terminal repeat are cotransfected with one of the reporter plasmids into CV1 cells, which lack significant levels of endogenous TR.

CV-1 cells are co-transfected with the reporter construct tk-CAT, tk-TRE_p-CAT or tk-TRE_{m3}-CAT; the respective expression plasmid (RS-rTR_a or RS-v-erbA) and the internal reference plasmid RSV-βGAL. In the control experiments, a construct carrying the rTR_a coding sequences in reverse orientation (RS-3'-5') is used.

Transfection of tk-TRE_p-CAT or the parental vector tk-CAT results in a high basal level of CAT activity that is only marginally stimulated by the addition of thyroid hormone. In contrast, cotransfection with the TR expression vector RSV-rTR_a results in marked effects on tk-TRE_p-CAT expression. In the absence of thyroid hormone, there is observed an 80% decrease in basal CAT activity (referred to as "low basal level activity"), indicating that TR expression provokes a ligand-independent inhibitory effect on transcription. Addition of a thyroid hormone, triiodothyronine [T₃], to a

-32-

final concentration of 100 nM results in a 20 fold stimulation of tk-TRE_p-CAT. This corresponds to a 3-5 fold stimulation over the basal level of activity obtained in the absence of TR expression.

5 The regulatory function of the rTR α is not restricted to the TRE_p; the TRE from the rat growth hormone gene is also able to sustain hormone-independent and dependent transcriptional responses. This functional assay enables a direct determination of the putative
10 transcriptional activity of the v-erbA oncogene product. Since v-erbA has lost its ability to bind thyroid hormone but retains an intact DNA binding domain, it is reasonable to expect that it would function as a constitutively active TR. Unexpectedly, cotransfection
15 of v-erbA with either reporter plasmid does not stimulate the transcription, but rather resembles the negative regulatory effects of rTR α in the absence of hormone. Thus, in cells expressing v-erbA, CAT activity is reduced by 80% from the high basal level, and can not be relieved
20 by the addition of T₃.

25 To identify the effect of different mutations in v-erbA on the altered properties of this protein (relative to its progenitor, TR), and to further dissect the processes of activation and repression, chimeric receptors of the v-erbA oncogene [see Damm et al., EMBO J. Vol. 6, pp. 375-382 (1987) and Vennström et al. J. Virol. Vol. 36, pp. 575-585 (1980)], and the rat TR α [Thompson et al., (1987), supra] are constructed. A schematic representation of the structure of the rat TR α /v-erbA chimeric proteins is presented in Figure 5A. Numbers on top of each construct indicate amino acid positions. The black bar indicates the deletion of 9 amino acids in v-erbA, resulting in fusion proteins of 401 amino acids compared to the 410 amino acid of the

-33-

protein with intact carboxy-terminus. In Figure 5B, positive and negative regulation of CAT activity from tk-TRE_p-CAT is shown, using the indicated expression vectors. The histogram summarizes the average values of 5 2-6 independent transfection experiments. Stippled bars in the histogram indicate the presence of no hormone; while striped bars in the histogram indicate the presence of 100 nM T₃.

From amino acids 154 to 410, v-erbA differs 10 from rTR α in 26 amino acids and a deletion of 9 amino acids close to the carboxy-terminus. Swapping this region of rTR α with v-erbA gives rise to the hybrid TR(154)erbA (Fig. 5A), whose properties are virtually identical to the v-erbA homologue (Fig. 5B). Thus, the 15 mutations in the DNA binding domain and flanking amino acids are not crucial to the v-erbA phenotype.

Substitution of an internal region of rTR α ligand binding domain (at amino acids 154-316), creates a 20 T₃ responsive hybrid (TR(154/316)erbA) that functions like the natural receptor. In contrast, replacement of the carboxy-terminal >3 amino acids of rTR α with the corresponding sequence of v-erbA, containing the 9-amino-acid deletion and additional 11 amino acid differences, yields the hybrid protein TR(317)erbA with suppressor 25 properties identical to the viral oncogene product.

To examine the effect of v-erbA on the function of endogenous thyroid receptor, cotransfection studies in CV1 cells are performed. The reporter gene tk-TRE_p-CAT (0.5 μ g) is cotransfected into CV-1 cells with 1 μ g of 30 rTR α expression vector and the internal control plasmid RSV- β -GAL. In addition, a 10-fold excess (10 μ g) of the expression plasmids indicated in Figure 6 is cotransfected with rTR α . In the run designated by (-), 10 μ g of the control plasmid, RS-3'-5', is used. The

-34-

average values of 2-6 independent transfection experiments are shown in the histogram in Figure 6. All experiments are performed in the presence of 100 nM T₃.

As shown in Figure 6A, a 10-fold molar excess 5 of v-erbA reduces by 90% the thyroid hormone dependent induction of the reporter gene transcription by rTR α . The hybrid constructs TR(154)erbA and TR(317)erbA also exhibit v-erbA-like activities, provoking a virtually complete repression of the T₃ and rTR α induced stimulation 10 of the reporter gene. The activity is, however, dependent on the presence of an intact DNA-binding region since the DNA-binding domain mutant 195(154)erbA, fails to compete.

Similarly, T₃ induction is blocked by v-erbA and 15 the chimeric constructs when the TRE_p is placed in the context of the MTV promoter. One prediction of these results is that an inverse relationship exists between the activity of the TR and the concentration of the competitor product. To examine this prediction, varying 20 molar ratios of TR(154)erbA and the rTR α expression vector were cotransfected and hormone responsiveness was assessed. Thus, the reporter gene tk-TRE_p-CAT (0.5 μ g) was cotransfected into CV1 cells with 1 μ g of expression vector RS-rTR α and increasing quantities of the non- 25 hormone binding competitor TR(154)erbA. The amounts of RSV-promoter was held constant in all transfections by the addition of the control plasmid, RS-3'-5'. Shown are the average values of three independent transfection experiments. Cells were grown in the presence of 100 nM 30 T₃.

As one might expect, increasing quantities of TR(154)erbA lead to decreasing activity of the rTR α (see Fig. 6B). In this assay, even small amounts of

-35-

TR(154)erbA are potent, with a 3:1 plasmid ratio completely blunting the hormone induced response.

Although it is generally assumed that the ability of a hormone receptor to bind DNA is ligand dependent [Evans, Science 240, 889 (1988)], the results presented herein, as well as previous observations [Lavin et al., J. Biol. Chem. 263, 9418 (1988)] challenge this convention. The downregulation of transcription from the responsive promoter is presumably a consequence of the ability of the receptor to recognize and bond to its cognate response element in the absence of hormone. Two pieces of evidence support this proposal. First, an intact DNA binding domain is necessary for both the gel retardation experiments and the observed transcriptional effects. Second, in the absence of the response element no significant repression is observed, whereas a tandem copy of the TRE potentiates both positive and negative transcriptional effects. Although positive synergism has been observed by glucocorticoid and estrogen receptors and their respective response elements [Schüle et al., Science 242, 1418 (1988) and Strähle et al., EMBO J. 7 3389 (1988)] the negative synergism observed here is without apparent precedent.

25 Example 5: Retinoic Acid Receptor Mediated Negative Regulation

To investigate the possible positive and/or negative interaction of RAR α with TR α and v-erbA, CV-1 cells are cotransfected with the RAR α and reporter plasmid in the presence of TR α or v-erbA (Fig 7). In the Figure, TR α or v-erbA compete with the RA induced transcriptional activation by RAR α . RAR α expression vector (1.0 μ g) is cotransfected with reporter plasmid AMTV-TRE_p-CAT (1.0 μ g) along with TR α (5.0 μ g) or with v-

-36-

erbA (5.0 µg). Plasmids are introduced into CV-1 cells (maintained in DME medium supplemented with 5% calf bovine serum), 5 x 10³ per 10.0 cm dish, by calcium phosphate precipitation.

5 The expression plasmids, RAR_a TR_a and v-erbA are under control of the RSV promoter as previously described by Damm et al. in Nature, Vol 339, 593 (1989) and Umesono et al., in Nature, Vol 335, 262 (1988). The cells were cultured for 36 hours in Dulbecco-modified Eagle medium containing 10% resin-charcoal stripped calf bovine serum [Samuels et al, Endocrinology, Vol 105, 80 (1979)] with or without hormone as indicated and subsequently prepared for CAT activity through three cycles of freeze thawing as described by Gorman et al, Mol. Cell. Biol., Vol 2, 1044 (1982). An aliquot of the cell extracts was normalized by β-gal activity prior to carrying out the CAT assay. The hormone is added at a final concentration of 100nM. These data are the average of 4 independent experiments.

20 A 5 fold molar excess of TR_a reduces the RA dependent induction in CAT activity by 90%. No inhibition of transcription is observed when both T3 and RA are added simultaneously. Therefore, in the absence of T3, the TR_a prevents the RA induced activation of gene expression by the RAR_a, whereas in the presence of T3, one observes activation, presumably through the TR_a. Similar observations for the TR inhibition of RAR activation have recently been observed by Graupner et al., Nature, Vol 340, 653 (1989) and Brent et al., The New Biologist, Vol 1, 329 (1989). A similar competition of the RA induced gene activation is observed when v-erbA is cotransfected along with the RAR_a.

25 To investigate whether one could confer a dominant negative effect directly onto the RAR_a, mutant

-37-

RAR α s are created consisting of a series of RAR truncations as well as a hybrid RAR α -erbA fusion. Since the RAR functions as a ligand dependent transcription factor, a mutant that contains an alteration or deletion in the ligand binding domain but with an intact DNA binding domain may confer a dominant negative phenotype.

5 in the ligand binding domain but with an intact DNA binding domain may confer a dominant negative phenotype. In fact, the results set forth in Example 4 above demonstrate that replacing the ligand binding domain, located in the carboxyl terminus of the TR α , with the

10 carboxyl terminus of v-erbA results in a hybrid TR α -erbA molecule that functions as a dominant negative mutant of the TR α . Therefore, a similar fusion between RAR α and v-erbA was constructed by replacing the ligand binding domain of the RAR α , located in the carboxyl terminal,

15 with the carboxyl terminus of v-erbA (Fig 8). The hybrid RAR α -erbA fusion was constructed by removing the N-terminus and DNA binding domain of TR317-erb- λ , see Damm et al, Supra, and replacing it with the corresponding N-terminus and DNA-binding domain the RAR α (thus creating a

20 RAR α -erbA hybrid protein). Truncation mutants give the last amino acid of RAR α before the insertion of a translation stop signal at the indicated position. The RAR 185 and 203 truncation mutants were constructed by using unique restriction sites present in the wild type receptor whereas RAR 153 was constructed by inserting a stop codon at position 153 RAR α following creation of a unique Xho site at this position. Retinoic acid was added at a final concentration of 100nM.

25

30 In the transactivation experiments, a positive response corresponds to a 25 fold increase in CAT activity upon retinoic acid addition. A negative response corresponds to no transactivation upon retinoic acid addition. In the competition experiments, a positive response corresponds to greater than an 80%

-38-

antagonism of the retinoic acid induced transactivation, while a negative response corresponds to no competition upon retinoic acid addition.

5 The RAR α -erbA protein does not act by itself as a transcriptional activator whether hormone is present or absent. However, when the RAR α -erbA fusion is cotransfected with the RAR α , it functions as a RAR α antagonist. See Figure 9.

10 CV-1 cells are cotransfected with RAR expression vector (1.0 μ g), AMTV-TRE $_p$ -CAT reporter plasmid (see Umesono et al, Supra) (5.0 μ g), reference plasmid (5.0 mg), along with increasing amounts of RAR α -erbA and carrier plasmid up to 20.0 mg. The addition of RSV-promoter is held constant in all transfections with the addition of the carrier plasmid. The \pm maximal response refers to CAT induction observed with the RAR wild type receptor in the presence of 100 nM RA. This activation corresponds to a RA induction of 25 fold. All data are the average of 4 independent experiments.

15 RAR α -erbA is also capable of antagonizing the RA induced activation of the RAR β and RAR γ . Therefore, replacement of the carboxyl terminus of RAR α with the carboxyl terminus of v-erbA confers a dominant negative phenotype onto the RAR α . In contrast, RAR mutants consisting of a series of carboxyl terminal truncations do not act as transcriptional activators when transfected by themselves nor do they function as RAR α competitors when transfected in conjunction with the RAR α . These data on the RAR truncations are in part at odds with the recent observation of Espeseth et al., *Genes and Dev.*, Vol. 3, 1647 (1989), who reported that an RAR α mutant, virtually identical to RAR-185, gave rise to a small percentage of stable F9 clones that did not differentiate in response to RA and therefore, hypothesized that this

-39-

RAR truncation mutant functioned as a dominant negative RAR.

The properties of the RAR α -erbA fusion along with the v-erbA and TR α , are further investigated by examining their ability to repress/antagonize an endogenous RAR(s). F9 cells have been established as a cellular model for RA dependent differentiation. They contain receptors for the α , β , and γ subtypes of the RAR family; RAR α and RAR γ are present in undifferentiated stem cell whereas RAR β is induced upon RA treatment. See, for example, Strickland and Mahdavi, in Cell, Vol 15, 393 (1978); Sporn et al., in The Retinoids, Vol 1-2, Academic Press (Orlando, FL, 1984); and Hu and Gudas in Mol. Cell. Biol., Vol 10, 391 (1990). Transfection of either RAR α -erbA, TR α or v-erbA into F9 cells results in a strong inhibition of the RA induced transactivation (Fig 10). F9 cells (maintained in DMEM supplemented with 10% CBS) are transfected by the calcium phosphate method with the reporter Δ MTV-TRE $_p$ -Luc (5.0 μ g), 5.0 μ g of either the control plasmid (RSV-CAT), or RSV-TR α , RSV-verba or RSV RAR α -erbA. 5.0 μ g of reference plasmid and 5.0 μ g of carrier plasmid. Cells are cultured for 24 hours in the presence or absence of 100 nM RA as indicated. The reporter construct is exactly the same as Δ MTV-TRE $_p$ -CAT except that the gene encoding firefly luciferase [see DeWet et al., Mol. Cell. Biol., Vol 7, 725 (1987)] has been substituted for CAT in the reporter plasmid. Cells were cultured for 24 hours following the addition of the hormone and subsequently harvested and assayed for luciferase as described by Hollenberg et al., in Cell, Vol 55, 899 (1988). Data are the average of 4 independent measurements.

-40-

Example 6: Glucocorticoid Receptor-v erbA and GR- β Gal Fusion Proteins

The above observations that the RAR α -erbA fusion protein functions as a dominant negative RAR, in conjunction with the ability of TR α -erbA hybrid to function as a TR α inhibitor, suggests that steroid-erbA hybrid receptors may provide a general approach for creating specific hormone receptor antagonists. Therefore, a fusion between GR and erbA was created (GR-erbA, Fig 11) by substituting the carboxyl terminus of v-erbA for the ligand binding domain of the GR.

In the Figure, wild type GR is shown at top with numbers indicating amino acid positions. The DNA and ligand binding domains are also indicated. The hybrid GR-erbA fusion is constructed by removing the ligand binding domain of the GR and replacing it with the carboxyl terminus of v-erbA, similar to the RAR-erbA fusion protein described above. The three truncation mutants give the last amino acid before the carboxyl terminal nonsense peptides. For GR-532 β gal, *E. coli* β gal was fused in frame to position 532 of the GR as described by Oro et al. in Cell, Vol 55, 1109 (1988). It encodes a protein that expresses β -galactosidase as well as the glucocorticoid receptor properties reported by Oro et al, Supra.

For the transactivation experiments, CV-1 cells are cotransfected with expression vector (1.0 μ g), the reporter, MTV-Luc (5.0 μ g), RSV-CAT (5.0 μ g) as the internal control and carrier plasmid up to a total of 20.0 μ g. Data is reported as \pm maximal response and refers to luciferase induction observed with the GR wild type in the presence of the synthetic glucocorticoid, dexamethasone at 1×10^{-7} M. This activation corresponds to an induction of 3000 fold.

-41-

For the competition experiments, CV-1 cells are cotransfected with 1.0 μ g of the GR expression vector, 5.0 μ g of MTV reporter, 5.0 μ g of competitor along with 5.0 μ g of RSV-CAT as the internal control and carrier plasmid up to a total of 20.0 μ g. Dexamethasone was added at a final concentration of 1×10^{-7} M. The response refers to a % antagonism of luciferase activity with the wild type receptor in the presence of a nonspecific competitor being equal to 0%. All data in Figure 11 are the average of four independent experiments.

The fusion protein does not activate a glucocorticoid responsive reporter gene when glucocorticoids are present or absent. However, when GR-erbA is cotransfected with GR, it functions as a GR antagonist; a 5-fold molar excess of GR-erbA reduces by 87% the dexamethasone induction of a reporter gene.

For comparison, the properties are examined of a series of GR truncation mutants to act as dominant negative competitors as well as transcriptional activators. Truncations in the carboxyl terminus result in a mutant receptor that either does not activate transcription (GR487), or result in mutants that are constitutively active receptors (GR515, GR532). When the GR truncations are cotransfected along with the wild type GR, they have either no inhibitory effect or at best a slight suppressive effect upon dexamethasone induced transactivation.

To examine whether the properties exerted by placing the carboxyl terminus of GR could be substituted by another polypeptide, β -Gal was fused in frame to the carboxyl terminus of the GR at position 532. This GR-532 β Gal fusion protein has previously been shown to function as a negative regulator of GR transcription (See

-42-

Example 3). However, this β -Gal fusion protein is constitutively active similar to the parental truncation and it reduces the GR activation by only 60%. Therefore, the ability and usefulness of the GR truncations and β -Gal fusions to act as dominant negative repressors is diminished primarily by their constitutive activity as well as their weak ability to act as GR competitors. In contrast, GR-erbA is the only mutant receptor that contains no transcriptional activity in the absence of ligand and functions to block the dexamethasone induced transactivation. In addition, GR-erbA is able to act as a very potent competitor against a constitutively active GR receptor, such as GR532, and further supports its potential to function as a dominant negative inhibitor.

The foregoing description details specific methods that can be employed to practice the present invention. Having detailed specific methods initially used to identify, isolate, characterize, prepare and use the receptors hereof, and a further disclosure as to specific entities, and sequences thereof, the art skilled will well enough know how to devise alternative reliable methods for arriving at the same information and for extending this information to other intraspecies and interspecies related receptors. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.

US 90/03113

IPEN/US

03 JUN 1991

-43-

CLAIMS:

1. A trans-repressing analog receptor of the steroid/thyroid superfamily of receptors, said analog comprising:

5 (1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of a wild type receptor, and

10 (2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said second sequence is selected from:

15 (a) a polypeptide which has at least about 90 % as many amino acids as the ligand binding domain of the carboxy-terminal portion of said wild type receptor; wherein ~~said polypeptide and~~ has less than about 60 % amino acid identity relative to the carboxy-terminal domain of said wild type receptor over either:

20 (i) the entire length of said polypeptide, if shorter than the carboxy-terminal domain of said wild type receptor, or

25 (ii) any segment of said polypeptide having the same length as the carboxy-terminal domain of said wild type receptor, or

30 (b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the v-erbA protein as defined by amino acid numbers 555-639 (see Figure 1);

35 provided that when said wild type receptor is a glucocorticoid receptor, said second amino acid sequence is not (a).

142
143
144

-44-

2. An analog receptor according to claim 1 wherein said hormone response element is operatively associated with a promoter which is subject to trans-repression.

5 3. An analog receptor according to claim 1 having substantially no transcriptional activation activity in the presence or absence of ligand.

10 4. An analog receptor according to claim 1 wherein said first amino acid sequence is the DNA-binding domain of said wild type receptor.

15 5. An analog receptor according to claim 4 wherein said wild type receptor is selected from: a retinoic acid receptor, a thyroid hormone receptor, a vitamin D₃ receptor, a glucocorticoid receptor, a mineralocorticoid receptor, an estrogen receptor, an estrogen-related receptor, an aldosterone receptor, an androgen receptor, or a progesterone receptor.

20 6. An analog receptor according to Claim 5 wherein said DNA-binding domain is derived from: 1) a glucocorticoid receptor, 2) a thyroid^{hormone} receptor, or 3) a retinoic acid receptor.

25 7. An analog receptor according to Claim 6 wherein said DNA-binding domain is derived from the human glucocorticoid receptor.

8. An analog receptor according to Claim 6 wherein said DNA-binding domain is derived from the thyroid receptor.

30 9. An analog receptor according to Claim 6 wherein said DNA-binding domain is derived from the retinoic acid receptor.

10. An analog receptor according to Claim 1 wherein said first amino acid sequence is derived from said wild type receptor, and wherein said analog receptor



has substantially no transcriptional activation activity in the presence or absence of ligand.

11. An analog receptor according to Claim 10 wherein said carboxy-terminal domain is obtained from a polypeptide.

5 12. An analog receptor according to Claim 11 wherein said polypeptide is at least a portion of the beta-galactosidase polypeptide.

13. An analog receptor according to Claim 10 wherein said carboxy-terminal domain comprises at least the 84 C-terminal amino acids of the C-terminal portion of the *v-erbA* protein.

10 14. A process for preparing an analog receptor according to Claim 1, said process comprising:

expressing, in a recombinant host cell, transfected DNA encoding said receptor.

15 15. A process according to Claim 14 further comprising: recovering and purifying said analog receptor to enable its use in assays that measure extrinsically induced biofunctionality of said analog receptor.

16. A DNA molecule that is a recombinant DNA molecule or a cDNA molecule encoding an analog receptor according to Claim 1.


20 17. An expression vector operatively harboring DNA according to Claim 16.

18. A recombinant host cell transfected with an expression vector according to Claim 17.

25 19. A cell culture comprising cells according to Claim 18 and an extrinsic support medium assuring the viability of said cells.

20 20. A non-human transgenic mammal, having disease symptoms due to an inability to respond normally to a steroid or thyroid hormone, wherein at least a subset of the cells of said mammal are capable of expressing an analog receptor of the steroid/thyroid superfamily of receptors according to any one of Claims 1 to 13 for one of said hormones, and wherein said analog receptor has trans-repression activity greater than that of its corresponding wild type receptor and trans-activation activity less than that of its corresponding wild type receptor.

30 21. Method for converting a wild type hormone receptor into a trans-repressing analog receptor of the steroid/thyroid superfamily of



receptors according to any one of claims 1 to 13 said method comprising:
replacing the ligand binding domain of said wild type receptor with
at least the 84 carboxy terminal amino acids of the *v-erbA* protein as
defined by amino acid numbers 313-398 (see Figure 1).

- 5 22. Method for converting a wild type hormone receptor into a trans-repressing analog receptor of the steroid/thyroid superfamily of receptors according to any one of claims 1 to 13 said method comprising:
replacing the ligand binding domain of said wild type receptor with a polypeptide which has at least 90% as many amino acids as the ligand
10 binding domain of the carboxy-terminus of said wild type receptor and less than about 60% amino acid identity relative to the carboxy-terminus of said wild type receptor over either:
 (i) the entire length of said polypeptide, if shorter than the carboxy-terminus of said wild type receptor, or
15 (ii) any segment of said polypeptide having the same length as the carboxy-terminus of said wild type receptor.
23. A method for blocking the transcriptional activation of a hormone response element in a cell, said method comprising
contacting said cell with an analog receptor according to Claim 1.
- 20 24. A method for blocking the transcriptional activation by a wild type receptor of the steroid/thyroid superfamily of receptors of a hormone response element present in a cell, said method comprising
 (a) substantially deleting the ligand binding domain of said wild type receptor,
25 (b) operatively linking the modified receptor of step (a) at the carboxy-terminal end thereof to at least the 84 carboxy terminal amino acids of the *v-erbA* protein as defined by amino acid numbers 313-398 (see Figure 1) to produce a fusion protein, and thereafter
 (c) contacting said cell with an effective amount of said fusion
30 protein.
25. A method for blocking the transcriptional activation by a wild type receptor of the steroid/thyroid superfamily of receptors of a hormone response element present in a cell, said method comprising
 (a) substantially deleting the ligand binding domain of said wild
35 type receptor,
 (b) operatively linking the modified receptor of step (a) at the carboxy-terminal end thereof to a polypeptide which has at least about 90% as many amino acids as the ligand binding domain of said wild type receptor, and less than about 60% amino acid identity relative to the



ligand binding domain of said wild type receptor over either

(i) the entire length of said polypeptide, if shorter than the

ligand binding domain of said wild type receptor, or

(ii) any segment of said polypeptide having the same length as the

5 ligand binding domain of said wild type receptor to produce a fusion protein, and thereafter

(c) contacting said cell with said fusion protein.

26. A method for identifying the response element and/or function of a receptor for which the associated response element and/or function 10 is not known, said method comprising:

comparing the response of a test system which is responsive to wild type receptor when said test system is treated with:

(I) wild type receptor, or

(II) trans-repressing analog receptor of the steroid/thyroid

15 superfamily of receptors according to any one of claims 1 to 13 wherein said trans-repressing analog receptor comprises:

(1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response element of said wild type receptor, and

20 (2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said second sequence is selected from:

(a) a polypeptide which has at least about 90% as many amino acids as the ligand binding domain of the carboxy-terminal portion of said wild 25 type receptor and less than about 60% amino acid identity relative to the carboxy-terminal domain of said wild type receptor over either

(i) the entire length of said polypeptide, if shorter than the carboxy-terminal domain of said wild type receptor, or

(ii) any segment of said polypeptide having the same length as the

30 carboxy-terminal domain of said wild type receptor; or

(b) at least the 84 carboxy-terminal amino acids of the



carboxy-terminal portion of the v-erbA protein as defined by amino acid numbers 313-398 (see Figure 1).

27. In an assay system for the determination of the presence of a specific wild type receptor, wherein more than one response element is capable of interacting with said wild type receptor, the improvement comprising inactivating, with respect to said assay, response element(s) which also respond to wild type receptor(s) other than said specific wild type receptor; wherein said response elements are inactivated by adding to said assay system an effective amount of a trans-repressing analog 10 receptor of the steroid/thyroid superfamily of receptors according to any one of claims 1 to 13 for each of said other receptor(s), wherein each of said trans-repressing analog receptors comprises:

(1) a first amino acid sequence which is a DNA-binding domain, through which said analog is capable of binding to a hormone response 15 element of a receptor other than said specific wild type receptor, and

(2) a second amino acid sequence which is positioned at the carboxy-terminal end of the DNA-binding domain, wherein said second sequence is selected from:

20 (a) a polypeptide which has at least about 90% as many amino acids as the ligand binding domain of the carboxy-terminal portion of said receptor other than said specific wild type receptor and less than about 60% amino acid identity relative to the carboxy-terminal domain of said receptor other than said specific wild type receptor over either

25 (i) the entire length of said polypeptide if shorter than the carboxy-terminal domain of said receptor other than said specific wild type receptor, or

(ii) any segment of said polypeptide having the same length as the carboxy-terminal domain of said receptor other than said specific wild type receptor; or

30 (b) at least the 84 carboxy-terminal amino acids of the carboxy-terminal portion of the v-erbA protein as defined by amino acid numbers 313-398 (see Figure 1).

28. A trans-repressing analog receptor of the steroid/thyroid superfamily of receptors according to any one of claims 1 to 13 and 35 substantially as herein described with reference to any one of the




Examples or to Figure 1.

29. A process for preparing an analog receptor of the steroid/thyroid superfamily of receptors according to any one of claims 1 to 13 substantially as hereinbefore described with reference to any one of the Examples or to Figure 1.

DATED this TWENTY-SECOND day of FEBRUARY 1993

The Salk Institute for Biological Studies

**Patent Attorneys for the Applicant
SPRUSON & FERGUSON**



1 / 13

FIG. I-1

(-171)	CGG CCC CCC GAA CAG CCA ACC GCG GAC CCA CGC CAC CCC GGT CAC CCC CCT	-121
Arg Gly Ala Glu Gln Pro Arg Ala Glu Pro Gly His Ala Gly Gln Ala Pro		
-40		
	GAG →	
	ERB A	
	GTC GTC CCC ACT GAC TGG GCA AGG ATC ACC GAG GAG CTT GCG ACT ACT GGT CCG CCC	-1
V _a 1 Val Ala Met Pro Val Val Val Ile Lys Thr Glu Gly Pro Ala Trp Thr Pro Leu Glu Pro		
-20		
	GAG →	
	GAG CAC ACT CGG TGG CTG GAT GCC AAC CAC AAA AGA AAG AGC CAA TGT TGC GTC AAG	-1
Glu Asp Thr Arg Trp Leu Asp Gly Lys His Lys Arg Lys Ser Ser Gln Cys Leu Val Lys		
10		
	AGC →	
	AGC ACC ATG TCA CGG TAC ATC CCT AGC TGC CTG GAC AAA GAT GAA CAG TGC GTC GTC TGT	120
Ser Ser Met Ser Gly Tyr Ile Pro Ser Cys Leu Asp Lys Asp Glu Gln Cys Val Val Cys		
30		
	GGG →	
	GGG GAC AAA GCC ACC GGC TAC CAC TAC CGC TGC ACC TCC TGC GAC CCC TGC GTC GTC TGT	120
Gly Asp Lys Ala Thr Gly Tyr His Tyr Arg Cys Ile Thr Cys Glu Gly Cys Lys Ser Phe		
50		
	TTC →	
	TTC CGT CGG ACC ATC CAG AAC MAC CTG CAC CCC ACC TAC TCC TGC ACG TAC GAT GGG TGC	240
Phe Arg Arg Thr Ile Gln Lys Asn Leu His Pro Thr Tyr Ser Cys Thr Tyr Asp Gly Cys		
70		
	TCC →	
	TCC GTC GAC AAG ATC ACC CCC AAC CAG TGC CAG CTG TGC CGC TTC AAG AAG TGC ATC	360
Cys Val Ile Asp Lys Ile Thr Arg Asn Gln Cys Gln Leu Cys Arg Phe Lys Lys Cys Ile		
90		
	Ser Val Gly Met Ala Met Asp Leu Val Leu Asp Asp Ser Lys Arg Val Ala Lys Arg Lys	120
110		

2 / 13

FIG. I-2

CTC ATC GAC AAC CGG GAG CGG CGA CGG AAC GAG GAC ATG ATC AAA TCC CTC CAG CAC
 Leu Ile Glu Glu Asn Arg Glu Arg Arg Glu Arg Glu Met Ile Lys Ser Leu Gln His 140
 130

CCC ACC CCC ACC CCA GAG GAG TGG GAG CTC ATC CAC GTC GTC ACC GAC CCC CAC CCC
 Arg Pro Ser Pro Ser Ala Glu Glu Trp Glu Leu Ile His Val Val Thr Glu Ala His Arg
 160
 150

ACC ACC AAC CCC CAC GGC AGC CAC TCG AAG CAG ACC AGC AAA TTC CTC CTC GAA GAT ATC
 Ser Thr Asn Ala Gln Gly Ser His Trp Lys Gln Arg Arg Lys Phe Leu Glu Asp Ile
 180
 170

CCT CAG TCC CCC ATG CCC TCC ATG CTT GAC CCC GAC AAA GTC GAC CTC GAG GCG TTC AGC
 Gly Gln Ser Pro Met Ala Ser Met Leu Asp Gly Asp Lys Val Asp Leu Glu Ala Phe Ser
 200
 190

DOMAIN 1 → **DOMAIN 2** ←

GAG TTT ACA AAA ATC ATC ACC CCC CCC ATC ACC CCC GTC GTC GAC TTT GGC AAA AAC CTC
 Glu Phe Thr Lys Ile Ile Thr Pro Ala Ile Thr Arg Val Val Asp Phe Ala Lys Asn Leu
 220
 210

CCC ATC TTC TCG GAC CTC CCC TCC GAC GAT CAG ATC ATC CTC AAC GCC TGC TGC ATC
 Pro Met Phe Ser Glu Leu Pro Cys Glu Asp Gln Ile Ile Leu Leu Lys Gly Cys Met
 240
 230

GAG ATC ATG TCG CTC CCC CCC GTC CGC TAC GAC CCC GAG ACC GAA ACG CTC ACC CTC
 Glu Ile Met Ser Leu Arg Ala Ala Val Arg Tyr Asp Pro Glu Ser Glu Thr Leu Thr Leu
 260
 250

ACC GGG GAA ATG CCC GTC AAA CCC GAG CAG TTG AAG AAC CCA GGG CTC GGG GTC TCT
 Ser Gly Glu Met Ala Val Lys Arg Glu Gln Leu Lys Asn Gly Leu Gly Val Val Ser
 280
 270

GAT CCC ATC TTC GAC CTC CCC GTC AAC TCG TCT GCC AAC CTC GAC ACC GAG GTC
 Asp Ala Ile Phe Asp Leu Gly Lys Ser Leu Ser Ala Phe Asn Leu Asp Asp Thr Glu Val
 300
 290

3 / 13

FIG. I-3

CCC	CTG	CAG	CCC	CTG	CTG	CTG	ATG	TCC	TCA	GAC	CGG	ACC	CTG	ATC	TGC	GTG	CAT		
Ala	Leu	Leu	Ala	Val	Leu	Leu	Met	Ser	Ser	Ser	Asp	Arg	Thr	Gly	Leu	Ile	Cys	Val	Asp
							310											320	

AAG	ATA	CAC	AAC	TGG	CAG	CAG	TGG	TAC	CTG	CTG	CCC	TTC	GAG	CAC	TAC	ATC	AAC	TAC	UGC
Lys	Ile	Glu	Glu	Cys	Gln	Glu	Ser	Tyr	Leu	Leu	Ala	Phe	Glu	His	Tyr	Ile	Asn	Tyr	Arg
							330											340	

AAA	CAC	AAC	ATT	CCC	CAC	TRC	TGG	TCC	AAC	CTG	CTG	ATC	AAC	GTC	CGG	GAC	CTG	CGC	ATC
Lys	His	Asn	Ile	Pro	His	Phe	Trp	Ser	Lys	Leu	Leu	Met	Lys	Val	Ala	Asp	Leu	Arg	Met
																		360	

ATC	GGC	CCC	TAC	CAC	CCC	AGC	CCC	TTC	CTG	CAC	ATG	AAG	GTC	GAG	TGC	CCC	ACG	GAG	CTC
Ile	Gly	Ala	Tyr	His	Ala	Ser	Arg	Phe	Leu	His	Met	Lys	Val	Glu	Cys	Pro	Thr	Glu	Leu
																		380	

CCC	CCA	AGG	AGG	TGT	AGA	GGG	CTA	CAG	ATT	TTG	GGG	ACT	ATA	TTG	CCC	TTT	CTA	TAG	TCC
Pro	Pro	Arg	Arg	Cys	Arg	Ala	Leu	Gln	Ile	Ile	Leu	Gly	Ser	Ile	Leu	Pro	Phe	Val	Ala
									390										

ATCCCTACAAAGAAAAACTTGTAAGCATTTCAAGTAGCTAAATGCTGAAATGCTCCACACT

TGAATGCCACAGATATTATCTTCTGTCTTATTCCCTGAAGTGTAAAGCAAATCTAACGAAATCATAGATTACTTGTCTTT 1359









FIG. 2






SUBSTITUTE SHEET

7 / 13

FIG. 5A

relative CAT-activity

FIG. 5B

8 / 13

FIG. 6A





FIG. 6B



9 / 13





FIG. 7

SUBSTITUTE SHEET


10 / 13

TRANSACTIVATION COMPETITION

FIG. 8



11 / 13

RAR α -erbA competition of RAR α **FIG. 9****SUBSTITUTE SHEET**

12 / 13


COMPETITION OF ENDOGENOUS RAR IN F9 CELLS

FIG. 10

SUBSTITUTE SHEET

13 / 13




FIG. II

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/03113

I. CLASSIFICATION OF SUBJECT MATTER (In several classification systems apply, indicate art):
 According to International Patent Classification (IPC) or to both National Classification and IPC
IPC(5): C07K 3/00, 13/00, 15/00, 17/00; C12P 21/00
U.S.CL.: 530/350,395; 435/69.1

II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched:	
		Classification Symbols
U.S.	530/350,395 435/69.1	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched:		

AUTOMATED PATENT SYSTEM AND DIALOG DATABASES.

III. DOCUMENTS CONSIDERED TO BE RELEVANT:

Category	Citation of Document, ¹⁴ with indication, where appropriate, of the relevant passages ¹⁵	Relevant to Claim No. 16
P.Y	Cell, Vol. 57, 30 June 1989. J.M. BERG 'DNA Binding Specificity of Steroid Receptors,' Pages 1065-1068. See entire document.	1-19
T	Cell, Vol. 57, 30 June 1990. K. UMESONO, et al., 'Determinants of Target Gene specificity for Steroid/Thyroid Hormone Receptors,' Pages 1139-1146.	1-19
P.Y	Cell, vol. 55, 21 October 1988. S.Y. TSAI, et al. 'Molecular Interactions of Steroid Hormone receptor with its Enhancer element: Evidence for Receptor dimer formation,' Pages 361-369. See entire document.	1-19
A	Cell, Vol. 52, 15 January 1988, R.M. EVANS et al. 'Zinc Fingers; Gilt by Association.' Pages 1-3.	1-19

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

*"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

*"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search:

06 September 1990

Date of Mailing of this International Search Report:

15 OCT 1990

International Searching Authority:

ISA/US

Signature of Authorized Officer
Thomas Cunningham
Thomas Cunningham, Ph.D.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

P.Y	DIALOG Accession No. 06979730. File NO. 155(Medline). Nature, Vol. 339(6226), 22 June 1989, K. DAMM, et al. "Protein Encoded by <u>v-erbA</u> functions as a thyroid hormone receptor antagonist," Pages 593-597. See abstract.	1-19
A	US, A, 4,818,684, EDELMAN, et al. 04 April 1989. See entire document.	1-19

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE*

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out¹, specifically:

3. Claim numbers because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING*

This International Searching Authority found multiple inventions in this International application as follows:
Group I, Claims 1-19, ~~drawn to~~ receptor and method of making it.

Group II, Claims 21-22, ~~drawn to~~ a second method of making a receptor.

Group III, Claim 20, drawn to a transgenic animal.

Group IV, Claim 26, drawn to a method of identifying a response element.

Group V, Claim 27, drawn to an assay system.

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-19

4. As all searchable claims could be searched without incurring an additional fee, the International Searching Authority did not incur payment of any additional fee.

Remarks on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.